Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's (NYSE:NVS) Gleevec/Glivec (imatinib).
- Although Qinlock did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, the drug showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events and improved tolerability.
- In addition, Qinlock had a more favorable safety profile than Pfizer Inc's (NYSE:PFE) Sutent (sunitinib), with fewer Grade 3/4 adverse events.
- Patients in the Qinlock arm reported less deterioration in role functioning and better outcomes than sunitinib.
- In patients with a KIT exon 11 primary mutations, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm.
- In the intention-to-treat (ITT) population, ripretinib demonstrated an mPFS of 8.0 months vs. 8.3 months.
- In patients with a KIT exon 11 primary mutations, ripretinib demonstrated an objective response rate of 23.9% vs. 14.6%, and 21.7% vs. 17.6% in the ITT populations.
- The FDA has approved Qinlock for advanced GIST patients who have received prior treatment with three or more kinase inhibitors.
- Price Action: DCPH shares traded 3.66% lower at $16.57 on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!